Cargando…
Rozanolixizumab: First Approval
Rozanolixizumab (rozanolixizumab-noli; RYSTIGGO(®)) is a high affinity humanized immunoglobulin G4 monoclonal antibody directed against human neonatal Fc receptor (FcRn). Administered subcutaneously, it is being developed by UCB Pharma for the treatment of autoimmune diseases and received its first...
| Autor principal: | |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Springer International Publishing
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10590285/ https://www.ncbi.nlm.nih.gov/pubmed/37656420 http://dx.doi.org/10.1007/s40265-023-01933-1 |